New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19

Remdesivir was recently approved by the Food and Drug Administration for the treatment of hospitalized patients with coronavirus disease 2019 (COVID-19). Remdesivir is the prodrug of an adenosine analogue that inhibits viral replication of several RNA virus families, including Coronaviridae. Preclin...

Descripción completa

Detalles Bibliográficos
Autores principales: Aleissa, Muneerah M., Silverman, Emily A., Paredes Acosta, Luisa M., Nutt, Cameron T., Richterman, Aaron, Marty, Francisco M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2020
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927874/
https://www.ncbi.nlm.nih.gov/pubmed/33139290
http://dx.doi.org/10.1128/AAC.01814-20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927874/
https://www.ncbi.nlm.nih.gov/pubmed/33139290
http://dx.doi.org/10.1128/AAC.01814-20

Ejemplares similares